Xenon Pharmaceuticals Inc.

9 hours ago · seekingalpha.com

Azetukalner's focal-seizure application gives Xenon Pharmaceuticals Inc. a potential path to its first commercial revenues, subject to FDA approval. The psychiatry setback weakens expansion potential, but I think epilepsy still provides a viable foundation for the bull case. XENE's liquid balance sheet should help it fund the remaining regulatory work and launch preparations.

9 hours ago · globenewswire.com

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).

4 days ago · proactiveinvestors.com

Xenon Pharmaceuticals Inc. (XENE:NASDAQ) shares were down 30%, on Friday morning after the company voluntarily halted new enrollment in major depressive disorder and bipolar depression studies. The events were consistent with azetukalner's known safety profile, Xenon said, but had not appeared in the earlier phase II X-NOVA depression trial.

4 days ago · zacks.com

Xenon files an FDA application for azetukalner in epilepsy as its depression studies face a temporary enrollment pause.

4 days ago · benzinga.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) submitted a New Drug Application to the U.S. Food and Drug Administration for its investigational drug azetukalner to treat focal seizures.

4 days ago · schaeffersresearch.com

Stock futures are mixed after last session's rebound, with several Fed officials scheduled to make remarks

4 days ago · barrons.com

Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.'

4 days ago · seekingalpha.com

Xenon Pharmaceuticals Inc. (XENE) Discusses Azetukalner NDA Submission for Focal Seizures and Psychiatry Program Update Transcript

5 days ago · reuters.com

Xenon Pharmaceuticals on Thursday said it has temporarily paused enrolling new patients in ​clinical studies testing its experimental drug for ‌major depression and bipolar disorder, following reports of mental and nervous system-related side effects.

5 days ago · globenewswire.com

VANCOUVER, BC and BOSTON, MA, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it has submitted a New Drug Application (NDA) for azetukalner in focal seizures (FS) to the U.S. Food and Drug Administration (FDA).